Paeonol attenuates progression of atherosclerotic lesion formation through lipid regulation, anti-inflammatory and antioxidant activities

doi:10.5246/jcps.2018.08.057

Abstract

Abstract:

As an active component extracted from Chinese herb moutan cortex and roots of paeonia lactiflora pallas, paeonol possesses many biological activities, including anti-inflammatory and vascular protection activities. In this study, athero-protectiveeffects of paeonol were investigated in apoliprotein E deficient (ApoE^–/–) mice through the entire course of atherosclerotic development. ApoE^–/–mice were divided into five groups and fed a high-cholesterol diet (HCD) for 5, 15 and 25 weeks. Then they were fed either paeonol or atorvastatin for 6 weeks. The methods, such as ELISA for serum lipid and cytokine analyses, Western blotting for protein expressions, and H&E and oil-red o-staining method, were used for evaluation of thoracic aorta lesion area. The results showed that paeonol could significantly reduce body weight, blood lipid, total cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL-C) in ApoE^–/–mice at all stages of the atherosclerosis process. Paeonol also reduced the levels of anti-inflammation factors, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-6, oxidized LDL cholesterol (ox-LDL), in serum. In paeonol groups, SOD was significantly increased, whereas MDA was decreased compared with the HCD group (P<0.01). Paeonol markedly attenuated the thickness of the lipid-rich plaque and down-regulated the expressions of VCAM-1 and MMP-9 in aorta of mice, suggesting that paeonol could inhibit formation of plaque and stabilize plaques. Taken together, paeonol appeared to have anti-dyslipidemia and anti-atherosclerotic effects by lipid regulation, and it could inhibit the effects of inflammation and oxidative stress on HCD-fed ApoE^–/–mice through the entire course of atherosclerotic development.

Key words: Paeonol, ApoE-deficient mice, Atherosclerosis, Lipids regulation, Anti-inflammatory, Antioxidant activities

CLC Number:

R962

Supporting:

Aiwei Song, Hongfei Wu, Min Dai . Paeonol attenuates progression of atherosclerotic lesion formation through lipid regulation, anti-inflammatory and antioxidant activities[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(8): 565-575.

References

[1] Libby, P.; Aikawa, M. Stabilization of atherosclerotic plaque: new mechanisms and clinical targets. Nat. Med. 2002, 8, 1257–1262.

[2] Lusis, A.J. Atherosclerosis. Nature. 2000, 407, 233–241.

[3] Kinkade, K.; Streeter, J.; Miller, F.J. Inhibition of NADPH Oxidase by Apocynin Attenuates Progression of Atherosclerosis. Int. J. Mol. Sci. 2013, 14, 17017–17028.

[4] Chobanian, A.V. Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hypercholesterolemia coexist. Hypertension. 1991, 18, 130–131.

[5] Stoll, G.; Bendszus, M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006, 37, 1923–1932.

[6] Yung, L.M.; Leung, F.P.; Yao, X.; Chen, Z.Y.; Huang, Y. Reactive oxygen species in vascular wall. Cardiovasc. Hematol. Disord. Drug Targets. 2006, 6, 1–19.

[7] Bao, M.H; Zhang, Y.W.; Zhou, H.H. Paeonol suppresses oxidized low-density lipoprotein induced endothelial cell apoptosis via activation of LOX-1/p38MAPK/NF-κB pathway. J. Ethnopharmacol. 2013, 146, 543–551.

[8] Shi, L.; Fan, P.S.; Fang, J.X.; Han, Z.X. Inhibitory effects of paeonol on experimental atherosclerosis and platelet aggregation of rabbit. Acta Pharmacol. Sin. 1998, 9, 555–558.

[9] Lau, C.H.; Chan, C.M.; Chan, Y.W.; Lau, K.M.; Lau, T.W.; Lam, F.C.; Law, W.T.; Che, C.T.; Leung, P.C.; Fung, K.P.; Ho, Y.Y.; Lau, C.B. Pharmacological investigations of the anti-diabetic effect of Cortex Moutan and its active component paeonol. Phytomedicine. 2007, 14, 778–784.

[10] Sun, G.P.; Wang, H.; Xu, S.P.; Wu, Q.; Chen, Z.D.; Wei, W. Anti-tumor effects of paeonol in a HepA-hepatoma bearing mouse model via induction of tumor cell apoptosis and stimulation of IL-2 and TNF-α production. Eur. J. Pharmacol. 2008, 584, 246–252.

[11] Pan, L.L.; Dai, M. Paeonol from Paeonia suffruticosa prevents TNF-alpha-induced monocytic cell adhesion to rat aortic endothelial cells by suppression of VCAM-1 expression. Phytomedicine Inter. J. Phytotherapy Phytopharmacology. 2009, 16, 1027–1032.

[12] Liu, Y.R.; Chen, J.J.; Dai, M. Paeonol protects rat vascular endothelial cells from ox-LDL-induced injury in vitro via downregulating microRNA-21 expression and TNF-αrelease. Acta Pharmacol. Sin. 2014, 35, 483–488.

[13] Wu, H.F.; Su, X.F.; Dai, M. Paeonol Inhibits Overpro-liferation of VSMCs in ox-LDL-Injured co-cultured System by Suppression of ET-1 Expression. Lat. Am. J. Pharm. 2015, 34, 1858–1865.

[14] Dai, M.; Zhi, X.M.; Peng, D.Y.; Liu, Q.Y. Inhibitory Effect of Paeonol on Experimental Atherosclerosis in Quails. China J. Chin. Mater. Med. 1999, 24, 488–490.

[15] Li, H.K.; Dai, M.; Jia, W. Paeonol attenuates high-fat-diet-induced atherosclerosis in rabbits by anti-inflammatory activity. Planta Med. 2009, 75, 7–11.

[16] Shan, L.M.; Zhang, J.C.; Zhao, Y.L.; Wang, H. Primary Mechanisms for Novel Compound Pivanampeta Against Atherosclerosis in Rat and Rabbit Model of Atherosclerosis. J. Chin. Pharm. Sci. 2004, 13, 1.

[17] Getz, G.S.; Reardon, C.A. Animal models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1104–1115.

[18] Kuehn, C.; Tauchi, M.; Stumpf, C.; Daniel, C.; Bäuerle, T.; Schwarz, M.; Kerek, F.; Steinkasserer, A.; Zinser, E.; Achenbach, S.; Dietel, B. Suppression of proatherogenic leukocyte interactions by MCS-18-Impact on advanced atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2016, 245, 101–110.

[19] Zhang, S.H.; Reddick, R.L.; Piedrahita, J.A.; Maeda, N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992, 258, 468–471.

[20] Nakashima, Y.; Plump, A.S.; Raines, E.W.; Breslow, J.L.; Ross, R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. Vasc. Biol. 1994, 14, 133–140.

[21] Nagarajan, S.; Burris, R.L.; Stewart, B.W.; Wilkerson, J.E.; Badger, T.M. Dietary soy protein isolate ameliorates atherosclerotic lesions in apolipoprotein E-deficient mice potentially by inhibiting monocyte chemoattractant protein-1 expression. J. Nutr. 2008, 138, 332–337.

[22] Choi, S.H.; Chae, A.; Miller, E.; Ntanios, F.; DeMaria, A.N.; Nissen, S.E.; Witztum, J.L.; Tsimikas, S. Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume: Observations From the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) Study. J. Am. Coll. Cardiol. 2008, 52, 24–32.

[23] Meir, E. Leitersdorf, Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1006–1014.

[24] Wang, Z.H.; Li, Y.F.; Guo, Y.Q. β3-Adrenoceptor activation attenuates atherosclerotic plaque formation in ApoE–/– mice through lowering blood lipids and glucose. Acta Pharmacol. Sin. 2013, 34, 1156–1163.

[25] Tabet, F.; Rye, K.A. High-density lipoproteins, inflammation and oxidative stress. Clin. Sci.(Lond). 2009, 116, 87–98.

[26] Mcneil, C.J.; Beattie, J.H.; Gordon, M.J.; Pirie, L.; Duthie, S.J. Nutritional B vitamin deficiency disrupts lipid metabolism causing accumulation of proatherogenic lipoproteins in the aorta adventitia of ApoE null mice. Mol. Nutr. Food Res. 2012, 56, 1122–1130.

[27] Ross, R. Atherosclerosis-An Inflammatory Disease. N. Engl. J. Med. 1999, 340, 115–126.

[28] Weber, C.; Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17, 1410–1422.

[29] Libby, P. Inflammation in atherosclerosis. Nature. 2002, 420, 868–874.

[30] Pirillo, A.; Norata, G.D.; Catapano, A.L. LOX-1, ox-LDL, and atherosclerosis. Med. Inf. 2013, 5, 519–530.

[31] Gotsman, I.; Stabholz, A.; Planer, D.; Pugatsch, T.; Lapidus, L.; Novikov, Y.; Masrawa, S.; Soskolne, A.; Lotan, C. Serum cytokine tumor necrosis factoralpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr. Med. Assoc. J. 2008, 10, 494–498.

[32] Victor, V.M.; Apostolova, N.; Herance, R.; Hernandez-Mijares, A.; Rocha, M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med. Chem. 2009, 16, 4654–667.

[33] Verreth, W.; De-Keyzer, D.P.; Geeraert, B.; Mertens, A.; Herregods, M.C.; Smith, G.; Desjardins, F.; Balligand, J.L.; Holvoet, P. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br. J. Pharmacol. 2007, 151, 347–355.

[34] Cybulsky, M.I.; Iiyama, K.; Li, H.; Zhu, S.; Chen, M.; Iiyama, M.; Davis, V.; Gutierrez-Ramos, J.C.; Connelly, P.W.; Milstone, D.S. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 2001, 107, 1255–1262.

[35] Johnson, J.L.; Devel, L.; Czarny, B.; George, S.J.; Jackson, C.L.; Rogakos, V.; Beau, F.; Yiotakis, A.; Newby, A.C.; Dive, V. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 528–535.

[36] Halade, G.V.; Jin, Y.F.; Lindsey, M.L. Matrix metallo-proteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol. Ther. 2013, 139, 32–40.